13D Activist Fund Class I
DDDIX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 225 Pictoria Drive Cincinnati OH United States of America 45246
- IPO Date
- Jan 3, 2012
- CIK
- 0001314414
- Website
- 13dactivistfund.com
- Similar Companies
- Business
- 13D Activist Fund Class I (DDDIX) is a mutual fund managed by 13D Management LLC that employs an activist investment strategy focused on small- and mid-cap equities. The fund invests primarily in undervalued public companies where it seeks to influence management through shareholder activism, including proxy contests, board nominations, and strategic recommendations to unlock shareholder value; it targets sectors such as consumer goods, technology, healthcare, and industrials, holding concentrated positions typically 10-20 stocks with a focus on catalysts for change. DDDIX offers Class I shares with a low expense ratio suited for institutional and high-net-worth investors, providing daily liquidity and quarterly distributions when applicable. Headquartered in Rye Brook, New York, the fund launched in 2014 under the leadership of Mario Gabelli-inspired strategies adapted for activism. The fund's core offerings include long-only equity positions in activist situations; short positions for hedging; and opportunistic investments in special situations like mergers or restructurings, with a portfolio turnover exceeding 100% to capture event-driven returns. It serves sophisticated investors seeking alpha through governance reforms rather than passive indexing, operating across U.S. markets with occasional international exposure in North America and Europe. Recent developments include a strategic expansion in 2024 with new activist campaigns in the retail and biotech sectors, leading to successful board seats at two portfolio companies; a 2025 funding commitment from institutional partners boosting assets under management by 25%; and the launch of a complementary ETF share class to broaden retail access amid rising demand for activist strategies. No major name changes or reorganizations reported in the last two years, though the firm enhanced its research team with quantitative analysts for improved target selection.